COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00582634
Recruitment Status : Completed
First Posted : December 28, 2007
Last Update Posted : November 19, 2019
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:
  • To determine if docetaxel and cisplatin can be administered in a dose intense manner in the adjuvant setting in resected non-small cell lung cancer
  • To evaluate the time to progression and overall survival
  • To evaluate toxicities of this chemotherapy combination in the adjuvant setting
  • To correlate XPD and ERCC1 polymorphisms with time to progression and toxicities in patients treated with this regimen

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer Drug: docetaxel and cisplatin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Adjuvant Cisplatin and Docetaxel in Non-small Cell Lung Cancer
Study Start Date : September 2004
Actual Primary Completion Date : December 2007
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Docetaxel followed by cisplatin
Docetaxel (75mg/m2) given IV followed by cisplatin (75mg/m2) given IV on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for 4 cycles.
Drug: docetaxel and cisplatin
Docetaxel (75mg/m2) followed by cisplatin (75mg/m2) on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for4 cycles.
Other Name: Taxotere

Primary Outcome Measures :
  1. Time to progression [ Time Frame: 36 months ]
  2. Overall survival [ Time Frame: 36 months ]
  3. Incidence of adverse events [ Time Frame: Baseline to 36 months ]

Secondary Outcome Measures :
  1. Correlate XPD and ERCC1 polymorphisms with time to progression and toxicities [ Time Frame: 36 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stage IB to IIIA non-small cell lung cancer completely resected within 4 to 8 weeks of initiating treatment on study
  • Performance Status ECOG 0 or 1
  • Peripheral neuropathy: < grade 1
  • Adequate blood cell counts
  • Adequate liver and hepatic function
  • Women of childbearing potential must have a negative pregnancy test.
  • Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter

Exclusion Criteria:

  • Patients with a history of severe hypersensitivity reaction to Docetaxel® or other drugs formulated with polysorbate 80.
  • Women who are breast-feeding.
  • Coexistent second malignancy or history of prior malignancy within previous 5 years (excluding basal or squamous cell carcinoma of the skin that has been treated curatively)
  • Uncontrolled cardiac disease or uncontrolled hypertension

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00582634

Layout table for location information
United States, Wisconsin
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
Layout table for investigator information
Principal Investigator: Anne Traynor, MD University of Wisconsin, Madison
Additional Information:
Layout table for additonal information
Responsible Party: University of Wisconsin, Madison Identifier: NCT00582634    
Other Study ID Numbers: H-2004-0248
CO04503 ( Other Identifier: University of Wisconsin Carbone Cancer Center )
H-2004-0248 ( Other Identifier: Institutional Review Board )
A534260 ( Other Identifier: UW Madison )
SMPH/MEDICINE ( Other Identifier: UW Madison )
First Posted: December 28, 2007    Key Record Dates
Last Update Posted: November 19, 2019
Last Verified: September 2015
Keywords provided by University of Wisconsin, Madison:
non small cell lung cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action